/
MCRB
$7.79+$0.71 (+10.03%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$68.6M
10M shares
52-week range
$5.31 – $29.98
10% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
2.02%
Moderate
Price (6 mo)
Loading chart…
Change$-444.21
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.3M | $34.5M | $33.2M | $144.9M | $0 | $0 | $0 | $789.0K |
| Cost of revenue | $96.0M | $0 | $90.6M | $0 | $0 | $19.3M | $3.5M | $4.1M |
| Gross profit | −$67.7M | $34.5M | −$57.4M | $144.9M | $0 | −$19.3M | −$3.5M | −$3.3M |
| Gross margin | -239.5% | 100.0% | -172.7% | 100.0% | — | — | — | -423.8% |
| R&D | $96.0M | $80.1M | $90.6M | $141.9M | $109.7M | $117.6M | $64.6M | $49.1M |
| Operating income | −$100.3M | −$71.9M | −$88.1M | −$64.5M | −$179.9M | −$195.1M | −$121.3M | −$94.0M |
| EBITDA | −$91.1M | −$62.2M | −$77.3M | −$56.7M | −$170.9M | −$181.4M | −$120.3M | $9.8M |
| Net income | −$98.9M | −$70.3M | −$89.1M | −$65.6M | −$250.2M | −$113.7M | −$146.6M | $5.7M |
| Net margin | -350.0% | -203.7% | -268.3% | -45.2% | — | — | — | 721.9% |
| EPS (diluted) | -48.57 | -24.81 | -22.34 | -14.30 | -46.29 | -17.77 | -18.86 | 0.64 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-7.51 | $-10.65–$-4.38 | 1 |
| 2027 | $358000 | $-6.58 | $-9.32–$-3.83 | 1 |
| 2028 | $358000 | $-11.41 | $-16.17–$-6.65 | 1 |
| 2029 | $249644 | $-8.80 | $-12.47–$-5.13 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Seres Therapeutics, Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
www.serestherapeutics.com- Employees
- 66
- IPO / List date
- Jun 26, 2015
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds MCRB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in MCRB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-04-22 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded MCRB yet.
